Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

LUN05-99

Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy Study

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • S. Jalal, S. Bhatia, L. Einhorn, R. Ansari, N. Bechar, R. Govindan, K. Koneru, P. Bedano, J. Wu, N. Hanna. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial from the Hoosier Oncology Group LUN05-99. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

Manuscripts/Articles:

  • Jalal, Shadia; Bedano, Pablo; Einhorn, Lawrence; Bhatia, Sumeet; Ansari, Rafat; Bechar, Naftali; Koneru, Karuna; Govindan, Ramaswamy; Wu, Jingwei; Yu, Menggang; Schneider, Bryan; Hanna, Nasser. Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group LUN05-99. Journal of Thoracic Oncology. 5(12):2008-2011, December 2010. doi: 10.1097/JTO.0b013e3181f77b6e